Pregled bibliografske jedinice broj: 1209235
Mycobacterium xenopi pulmonary disease in Croatia
Mycobacterium xenopi pulmonary disease in Croatia // ERS International Congress 2017
Milano, Italija: European Respiratory Society, 2017. str. 61-61 doi:10.1183/1393003.congress-2017.pa2737 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1209235 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Mycobacterium xenopi pulmonary disease in Croatia
Autori
Jankovic, Mateja ; Sabol, Ivan ; Zmak, Ljiljana ; Jakopovic, Marko ; Sola, Ana-Marija ; Popovic- Grle, Sanja ; Bulat-Kardum, Ljiljana ; Ticac, Brigita ; Vukic Dugac, Andrea ; Hecimovic, Ana ; Dzubur, Fedja ; Samarzija, Miroslav ; Carevic- Vladic, Vesna ; Sekula, Daniel
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Skup
ERS International Congress 2017
Mjesto i datum
Milano, Italija, 09.09.2017. - 13.09.2017
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
mycobacterium, Croatia
Sažetak
Background: clinical relevance of M. xenopi in Croatia seems to differ to other countries. Aims and objectives: to assess clinical relevance of M. xenopi, and differences between patients colonized with M. xenopi and those with M. xenopi pulmonary disease (PD) and identify factors that may favor the disease. Methods: Retrospective analysis of all Croatian residents with pulmonary M. xenopi isolated in the period from 2006 to 2016. American Thoracic Society guidelines were used to establish the definition of M. xenopi PD or colonization. Results: medical records were available for 188/326 (57.7%) patients with M. xenopi isolate. Of those 188, 48 had certain PD, and 117 had no disease. Out of 117 classified as no disease, 20 cases of active tuberculosis (TB) co-infection were excluded from further risk analysis. Overall median follow up was 47 month. Patients with low body mass index (BMI), bronchiectasies, or inhalation corticosteroid (ICS) therapy had 6 (p<0.001), 3 (p=0.013), and 2 (p=0.024) times higher likelihood of having M. xenopi PD, compared to colonization, respectively. 5-year survival amounted to 60% in both PD and colonization group. 10-years survival was lower in the colonization group (24% vs 54%) There were no significant differences in all-cause mortality and M. xenopi caused mortality with regard to different therapies administered (adequate therapy ; short duration adequate therapy ; inadequate/no therapy ; TB therapy). Conclusion: low BMI, ICS therapy, and bronchiectasies were associated with M. xenopi PD in comparison to colonization. Percentage of isolates meeting the PD criteria and overal survival of patients with PD, indicate that the pathogenicity of M. xenopy in Croatia is lower copmared to other countries.
Izvorni jezik
Engleski
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Klinika za plućne bolesti "Jordanovac",
Klinički bolnički centar Zagreb
Profili:
Brigita Tićac
(autor)
Miroslav Samaržija
(autor)
Sanja Popović-Grle
(autor)
Ljiljana Žmak
(autor)
Mateja Janković Makek
(autor)
Ana Hećimović
(autor)
Marko Jakopović
(autor)
Andrea Vukić Dugac
(autor)
Ljiljana Bulat-Kardum
(autor)
Ivan Sabol
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE